Flotetuzumab Expanded Access Program

Summary

The purpose of the Expanded Access program is to provide flotetuzumab to patients with acute myeloid leukemia (AML) for whom potential benefit justifies potential treatment risks.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications